Completed PHASE4 INTERVENTIONAL 2-arm NCT00379067

A Phase 4 Study With Tamsulosin OCAS to Assess Nighttime Voiding.

A Randomized, Double-blind, Placebo-controlled Study to Assess the Effect of Tamsulosin OCAS 0.4 mg Tablets, Once Daily on Nocturia, Compared to Placebo, in Patients With Lower Urinary Tract Symptoms Associated With Benign Prostatic Hyperplasia

Sponsor: Astellas Pharma Europe Ltd.

Conditions Benign Prostatic Hyperplasia

Interventions Placebo Tamsulosin OCAS

Updated 5 times since 2017 Last updated: Oct 8, 2014 Started: Oct 31, 2005 Primary completion: Nov 30, 2006 Completion: Nov 30, 2006

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT00379067, this PHASE4 trial focuses on Benign Prostatic Hyperplasia and remains completed. Sponsored by Astellas Pharma Europe Ltd., it has been updated 5 times since 2005, reflecting limited change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.

Status Flow

Change History

5 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE4
Jul 2024 — Sep 2024 [monthly]

Completed PHASE4
Jan 2021 — Jul 2024 [monthly]

Completed PHASE4
Jun 2018 — Jan 2021 [monthly]

Completed PHASE4
Jan 2017 — Jun 2018 [monthly]

Completed PHASE4

First recorded

Oct 2005

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Astellas Pharma Europe Ltd.
Astellas Pharma Inc
Boehringer Ingelheim

Data source: Astellas Pharma Inc

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

No location information available.